Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04501653 · ClinicalTrials.gov registry record · Early Phase 1
Precision Functional Brain Mapping in Psilocybin
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
NCT04501653 is a Early Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 11 participants.
The verdict
NCT04501653, a Early Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This project will employ functional brain imaging to study the mechanism and immediate and long-term effects of psilocybin, a serotonin receptor 2A agonist, on cortical and cortico-subcortical brain networks in healthy adults.
Interventions
- DRUG Psilocybin
- DRUG Methylphenidate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2023-03-19 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04501653
The ClinicalTrials.gov registry entry for NCT04501653 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Psilocybin is the first listed.
NCT04501653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04501653 about?
NCT04501653 is a clinical study titled "Precision Functional Brain Mapping in Psilocybin". This project will employ functional brain imaging to study the mechanism and immediate and long-term effects of psilocybin, a serotonin receptor 2A agonist, on cortical and cortico-subcortical brain networks in healthy adults.
What is the current status of trial NCT04501653?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2021-06-01. Estimated completion is 2023-03-19.
What interventions are being tested in trial NCT04501653?
The interventions under investigation include: Psilocybin (DRUG), Methylphenidate (DRUG).
Who is sponsoring clinical trial NCT04501653?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.